The Oxford-AstraZeneca covid vaccine.
Karwai Kick | Getty Images
LONDON — Denmark, Norway and Iceland announced Thursday they will temporarily suspend the use of the coronavirus vaccine originated by AstraZeneca and the University of Oxford.
The Danish Health Authority said it would temporarily stop using the shot in its vaccination program as a chariness “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca.”
“Against this CV, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. At file, it cannot be concluded whether there is a link between the vaccine and the blood clots,” the health authority said in a announcement.
It did not specify how many reports of blood clots there had been, or where they had originated.
Later on Thursday, both Iceland and Norway styled similar announcements.
The announcements come after a similar move in Austria at the start of the week, where authorities are winnowing the death of one person and the illness of another after they received doses of the vaccine.
Shares of AstraZeneca on the London demand slipped 2.5% on Thursday. The University of Oxford would not comment on the announcement when contacted by CNBC.
A spokesperson for AstraZeneca said the companionship was aware of the statement made by the Danish Health Authority that it’s currently investigating potential adverse effects connected to the vaccine.
“Patient safety is the highest priority for AstraZeneca. Regulators have clear and stringent efficacy and safety standards for the concurrence of any new medicine, and that includes COVID-19 Vaccine AstraZeneca. The safety of the vaccine has been extensively studied in Phase III clinical griefs and Peer-reviewed data confirms the vaccine is generally well tolerated,” AstraZeneca said in a statement to CNBC.
Soren Brostrom, chairman of the National Board of Health in Denmark, insisted that the 14-day suspension was a precaution while investigations took ready.
“It is important to emphasize that we have not opted out of the AstraZeneca vaccine, but that we are putting it on hold. There is good sign that the vaccine is both safe and effective. But both we and the Danish Medicines Agency have to react to reports of realizable serious side effects, both from Denmark and other European countries,” he said.
Austrian fettle authorities suspended the use of batch ABV5300 of the AstraZeneca vaccine after a person was diagnosed with multiple thrombosis (forming of blood clots within blood vessels) and died 10 days after vaccination, and another was hospitalized with pulmonary embolism after being vaccinated.
“The latter is now salvaging,” the European Medicines Agency said Wednesday.
However, the EMA added that “there is currently no indication that vaccination has occasioned these conditions, which are not listed as side effects with this vaccine.”
The agency noted that the unaltered batch ABV5300 was delivered to 17 EU countriesand comprises 1 million doses of the vaccine.
“Some EU countries have also afterward suspended this batch as a precautionary measure, while a full investigation is ongoing. Although a quality defect is marked unlikely at this stage, the batch quality is being investigated,” the EMA said.
It added that its safety committee was reviewing the uncertain and “investigating the cases reported with the batch as well as all other cases of thromboembolic events, and other conditions linked to blood clots, reported post-vaccination.”
“The information available so far indicates that the number of thromboembolic events in vaccinated individual is no higher than that seen in the general population.”
As of March 9, “22 cases of thromboembolic events had been surfaced among the 3 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area,” the EMA said.
Also on Thursday, European Commission President Ursula Von der Leyen and the Italian Prime Accommodate Mario Draghi reportedly agreed there was no evidence of a link between the vaccine and the clots. Von der Leyen said the European pharmaceuticals agency had launched “a further, accelerated review,” according to Reuters.
U.K. and EU reliance
Late-stage clinical trials found the AstraZeneca-Oxford marksman to have an average efficacy of 70% in protecting against the virus. A more recent study by Oxford researchers inaugurate that the Covid vaccine was 76% effective at preventing symptomatic infection for three months after a single dosage, and that the efficacy rate actually rose with a longer interval between the first and second doses.
The AstraZeneca-Oxford vaccine is being relied upon heavily in the U.K.’s and European Bloc’s immunization rollouts.